DE69636313D1 - Verwendung von Kristallformen von 2-Methylthienobenzodiazepinen - Google Patents

Verwendung von Kristallformen von 2-Methylthienobenzodiazepinen

Info

Publication number: DE69636313D1
Authority: DE; Germany
Prior art keywords: methylthienobenzodiazepines; crystal forms; crystal; forms
Prior art date: 1995-03-24
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired - Lifetime

Application number

DE69636313T

Other languages

English (en)

Other versions

DE69636313T2 (de

Inventor

Charles Arthur Bunnell

Barry Arnold Hendriksen

Samuel Dean Larsen

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Eli Lilly and Co Ltd

Eli Lilly and Co

Original Assignee

Eli Lilly and Co Ltd

Eli Lilly and Co

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1995-03-24

Filing date

1996-03-22

Publication date

2006-08-10

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23621056&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE69636313(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1996-03-22 Application filed by Eli Lilly and Co Ltd, Eli Lilly and Co filed Critical Eli Lilly and Co Ltd

2006-08-10 Application granted granted Critical

2006-08-10 Publication of DE69636313D1 publication Critical patent/DE69636313D1/de

2007-05-31 Publication of DE69636313T2 publication Critical patent/DE69636313T2/de

2016-03-23 Anticipated expiration legal-status Critical

Status Expired - Lifetime legal-status Critical Current

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia

Landscapes

Chemical & Material Sciences (AREA)
Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Engineering & Computer Science (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Medicinal Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Psychiatry (AREA)
Epidemiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Medicinal Preparation (AREA)

DE69636313T 1995-03-24 1996-03-22 Verwendung von Kristallformen von 2-Methylthienobenzodiazepinen Expired - Lifetime DE69636313T2 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US409566		1982-08-19
US40956695A	1995-03-24	1995-03-24

Publications (2)

Publication Number	Publication Date
DE69636313D1 true DE69636313D1 (de)	2006-08-10
DE69636313T2 DE69636313T2 (de)	2007-05-31

Family

ID=23621056

Family Applications (4)

Application Number	Title	Priority Date	Filing Date
DE69636313T Expired - Lifetime DE69636313T2 (de)	1995-03-24	1996-03-22	Verwendung von Kristallformen von 2-Methylthienobenzodiazepinen
DE69630324T Expired - Lifetime DE69630324T2 (de)	1995-03-24	1996-03-22	Verfahren und Kristallformen von 2-Methylthienobenzodiazepinen
DE69614426T Expired - Lifetime DE69614426T2 (de)	1995-03-24	1996-03-22	Kristallformen eines Thieno(2,3-B)(1,5)benzodiazepinderivates und Verfahren zu deren Herstellung
DE19681286T Withdrawn DE19681286T1 (de)	1995-03-24	1996-03-22	Neue Kristallform von Olanzapin

Family Applications After (3)

Application Number	Title	Priority Date	Filing Date
DE69630324T Expired - Lifetime DE69630324T2 (de)	1995-03-24	1996-03-22	Verfahren und Kristallformen von 2-Methylthienobenzodiazepinen
DE69614426T Expired - Lifetime DE69614426T2 (de)	1995-03-24	1996-03-22	Kristallformen eines Thieno(2,3-B)(1,5)benzodiazepinderivates und Verfahren zu deren Herstellung
DE19681286T Withdrawn DE19681286T1 (de)	1995-03-24	1996-03-22	Neue Kristallform von Olanzapin

Country Status (49)

Country	Link
US (1)	US5736541A (de)
EP (3)	EP1095941B1 (de)
JP (1)	JPH11502535A (de)
KR (1)	KR100399688B1 (de)
CN (1)	CN1065536C (de)
AP (1)	AP828A (de)
AR (2)	AR010448A1 (de)
AT (4)	ATE204280T1 (de)
AU (1)	AU706471B2 (de)
BG (1)	BG62619B1 (de)
BR (1)	BR9607790A (de)
CA (1)	CA2214005C (de)
CH (1)	CH690579A5 (de)
CO (1)	CO4650278A1 (de)
CZ (1)	CZ292688B6 (de)
DE (4)	DE69636313T2 (de)
DK (4)	DK0733635T3 (de)
EA (1)	EA000149B1 (de)
EE (1)	EE03489B1 (de)
EG (1)	EG23659A (de)
ES (3)	ES2159346T3 (de)
FI (1)	FI973750L (de)
GB (1)	GB2313835B (de)
HK (1)	HK1013988A1 (de)
HU (1)	HU224989B1 (de)
IL (1)	IL117610A (de)
IS (1)	IS1896B (de)
LT (1)	LT4349B (de)
LU (1)	LU90096B1 (de)
LV (1)	LV12018B (de)
MY (1)	MY114701A (de)
NO (1)	NO314663B1 (de)
NZ (1)	NZ306110A (de)
OA (1)	OA10510A (de)
PA (1)	PA8353701A1 (de)
PE (1)	PE44897A1 (de)
PL (1)	PL183723B1 (de)
PT (3)	PT1095941E (de)
RO (1)	RO118872B1 (de)
SE (1)	SE9703205D0 (de)
SI (4)	SI0733635T1 (de)
SK (1)	SK284143B6 (de)
SV (1)	SV1996000031A (de)
TR (1)	TR199701017T1 (de)
TW (2)	TW442488B (de)
UA (1)	UA44765C2 (de)
WO (1)	WO1996030375A1 (de)
YU (1)	YU49478B (de)
ZA (2)	ZA962344B (de)

Families Citing this family (84)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EG23659A (en) *	1995-03-24	2007-03-26	Lilly Co Eli	Process and crystal forms of methyl-thieno-benzodiazepine
US6274636B1 (en) *	1995-09-29	2001-08-14	Eli Lilly And Company	Method for treating a tic disorder
UA57727C2 (uk) *	1996-03-11	2003-07-15	Елі Ліллі Енд Компані	Спосіб лікування надмірної агресивності
EP0795330A1 (de) *	1996-03-11	1997-09-17	Eli Lilly And Company	Arzneimittel zur Behandlung von Schlaflosigkeit
EA000976B1 (ru) *	1996-03-25	2000-08-28	Эли Лилли Энд Компани	Композиция для снятия боли и способ снятия боли
CZ298398A3 (cs) *	1996-03-25	1999-06-16	Eli Lilly And Company	Farmaceutický přípravek
AU2542997A (en) *	1996-03-25	1997-10-17	Eli Lilly And Company	Anesthetic method
CN1219878A (zh) *	1996-03-25	1999-06-16	伊莱利利公司	治疗疼痛的方法
IL128956A0 (en) *	1996-09-23	2000-02-17	Lilly Co Eli	Olanzapine dihydrate D
ZA978515B (en) *	1996-09-23	1999-03-23	Lilly Co Eli	Intermediates and process for preparing olanzapine
EP1155696B1 (de) *	1997-04-15	2004-03-03	Eli Lilly And Company	Verwendung von Olanzapin zur Herstellung eines Arzneimittels zur Neuroprotektion
WO1998046596A1 (en) *	1997-04-15	1998-10-22	Eli Lilly And Company	Method for providing neuro-protective effects
ZA982917B (en) *	1997-04-15	1999-10-06	Lilly Co Eli	Method for treating cerebral focal stroke.
US20030022889A1 (en) *	1997-04-15	2003-01-30	Bymaster Franklin P.	Method for providing neuro-protective effects
USRE43932E1 (en)	1997-07-18	2013-01-15	Novartis Ag	Crystal modification of a N-phenyl-2-pyrimidineamine derivative, processes for its manufacture and its use
US6617321B2 (en)	1997-09-30	2003-09-09	Eli Lilly And Company	2-methyl-thieno-benzodiazepine formulation
IL141766A0 (en) *	1998-09-30	2002-03-10	Lilly Co Eli	2-methyl-thieno-benzodiazepine formulation
FR2802101B1 (fr)	1999-12-10	2003-02-28	Aventis Pharma Sa	Association de cymemazine et d'un neuroleptique atypique
DK1246827T3 (da) *	1999-12-28	2005-05-23	Cipla Ltd	Nye polymorfe former af olanzapin
US6348458B1 (en)	1999-12-28	2002-02-19	U & I Pharmaceuticals Ltd.	Polymorphic forms of olanzapine
US7022698B2 (en)	1999-12-28	2006-04-04	U & I Pharmaceuticals, Ltd.	Pharmaceutical compositions containing new polymorphic forms of olanzapine and uses thereof
AU2001243475A1 (en) *	2000-08-31	2002-03-13	Dr. Reddy's Laboratories Ltd.	Process for preparation of hydrates of olanzapine and their conversion into crystalline forms of olanzapine
AU2001282913A1 (en) *	2000-09-08	2002-03-22	Eli Lilly And Company	A method of treating weight gain associated with atypical antipsychotic use
US6740753B2 (en) *	2001-01-04	2004-05-25	Geneva Pharmaceuticals, Inc.	Olanzapine crystal modification
CA2464306A1 (en) *	2001-10-29	2003-05-08	Dr. Reddy's Laboratories Ltd.	Olanzapine dihydrate-ii a process for its preparation and use thereof
CH695862A5 (fr)	2001-12-24	2006-09-29	Sun Pharmaceutical Ind Ltd	Forme cristalline I de la methyl-4-(4-methyl-1-piperazinyl) 10H-thieno [2,3-b] [1,5] benzodiazepine.
WO2004089313A2 (en) *	2003-04-01	2004-10-21	Transform Pharmaceuticals, Inc.	Novel olanzapine forms and related methods of treatment
US7927613B2 (en) *	2002-02-15	2011-04-19	University Of South Florida	Pharmaceutical co-crystal compositions
US7790905B2 (en) *	2002-02-15	2010-09-07	Mcneil-Ppc, Inc.	Pharmaceutical propylene glycol solvate compositions
US20100311701A1 (en) *	2002-02-15	2010-12-09	Transform Pharmaceuticals, Inc	Pharmaceutical Co-Crystal Compositions
CA2477088A1 (en)	2002-02-22	2003-10-02	New River Pharmaceuticals Inc.	Active agent delivery systems and methods for protecting and administering active agents
JP4906233B2 (ja) *	2002-03-01	2012-03-28	ユニバーシティーオブサウスフロリダ	少なくとも１種の有効薬剤成分を含有する多構成要素固相
PL196814B1 (pl) *	2002-05-17	2008-02-29	Inst Farmaceutyczny	Sposób wytwarzania odmiany polimorficznej I olanzapiny i jej solwaty
WO2003101997A1 (en)	2002-05-31	2003-12-11	Geneva Pharmaceuticals, Inc.	Process of preparation of olanzapine form i
CN100360117C (zh) *	2002-06-21	2008-01-09	转化医药公司	具有提高的溶出度的药物组合物
SI21270A (sl)	2002-07-15	2004-02-29	Krka, Tovarna Zdravil, D.D., Novo Mesto	Kristalne oblike olanzapina in postopki za njihovo pripravo
PL202856B1 (pl) *	2002-12-20	2009-07-31	Adamed Spo & Lstrok Ka Z Ogran	Sposób otrzymywania farmaceutycznie czystej polimorficznej postaci I olanzapiny
AU2003300324A1 (en) *	2002-12-24	2004-07-22	Teva Pharmaceutical Industries Ltd.	Novel crystal forms of olanzapine, methods for their preparation and method for the preparation of known olanzapine crystal forms
US8183290B2 (en)	2002-12-30	2012-05-22	Mcneil-Ppc, Inc.	Pharmaceutically acceptable propylene glycol solvate of naproxen
US20060135547A1 (en) *	2003-03-12	2006-06-22	Toth Zoltan G	Stable pharmaceutical compositions of desloratadine and processes for preparation of polymorphic forms of desloratadine
ES2232331T1 (es) *	2003-03-12	2005-06-01	Biogal Gyogyszergyar Rt.	Procedimientos para la preparacion de formas polimorficas de desloratadina.
GB0314149D0 (en) *	2003-06-18	2003-07-23	Generics Uk Ltd	Novel amorphous forms
GB0326148D0 (en)	2003-11-10	2003-12-17	Lilly Co Eli	Morpholine derivatives
EP1684734A2 (de) *	2003-11-18	2006-08-02	3M Innovative Properties Company	Olanzapin-haltige transdermale arzneimittelabgabezusammensetzungen
US7425627B2 (en) *	2003-12-22	2008-09-16	Teva Pharmaceutical Industries Ltd.	Methods of synthesizing olanzapine
US20050272720A1 (en) *	2004-01-27	2005-12-08	Rolf Keltjens	Process for making olanzapine Form I
EP1709053B1 (de)	2004-01-27	2011-04-06	Synthon B.V.	Stabile salze von olanzapin
ES2253091B1 (es)	2004-07-27	2007-02-01	Inke, S.A.	Solvato mixto de olanzapina, procedimiento para su obtencion y procedimiento de obtencion de la forma i de olanzapina a partir del mismo.
WO2006027800A1 (en) *	2004-09-06	2006-03-16	Shasun Chemicals And Drugs Limited	A novel process for preparation of a pharmaceutically pure polymorphic form 1 of olanzapine
EA200701065A1 (ru) *	2004-11-16	2007-12-28	Элан Фарма Интернэшнл Лтд.	Инъецируемые составы, содержащие нанодисперсный оланзапин
SI1838716T1 (sl)	2005-01-05	2011-10-28	Lilly Co Eli	Olanzapin pamoat dihidrat
CZ200563A3 (cs) *	2005-02-02	2006-10-11	Zentiva, A. S.	Lécivý prípravek obsahující jako úcinnou slozku olanzapin a zpusob jeho výroby
AR053562A1 (es) *	2005-03-21	2007-05-09	Reddys Lab Ltd Dr	Proceso para la preparacion de la forma i cristalina de olanzapina
US20070021605A1 (en) *	2005-07-20	2007-01-25	Rolf Keltjens	Process and composition for making olanzapine form i
WO2007020080A1 (en) *	2005-08-17	2007-02-22	Synthon B.V.	A process for making olanzapine form i
GB0522474D0 (en) *	2005-11-03	2005-12-14	Actavis Group	A pharmaceutical formulation
HUP0501046A2 (en)	2005-11-11	2007-08-28	Egis Gyogyszergyar Nyilvanosan	Process for the preparation of olanzapine
US8367580B2 (en)	2006-03-07	2013-02-05	Ncr Corporation	Dual-sided thermal security features
US8222184B2 (en)	2006-03-07	2012-07-17	Ncr Corporation	UV and thermal guard
US8721202B2 (en)	2005-12-08	2014-05-13	Ncr Corporation	Two-sided thermal print switch
ES2279715B1 (es)	2005-12-26	2008-06-01	Laboratorios Lesvi, S.L.	Formulacion oral de olanzapina.
US7834176B2 (en)	2006-01-26	2010-11-16	Sandoz Ag	Polymorph E of Olanzapine and preparation of anhydrous non-solvated crystalline polymorphic Form I of 2-methyl-4(4-methyl-1-piperazinyl)-10H-thieno[2,3-b][1,5] benzodiazepine (Olanzapine Form I) from the polymorphic Olanzapine Form E
US20070293479A1 (en) *	2006-05-18	2007-12-20	Osinga Niels J	Olanzapine pharmaceutical composition
CL2007002807A1 (es) *	2006-09-29	2008-04-11	Synthon Bv	Composicion farmaceutica en estado solido que comprende olanzapina o una sal farmaceuticamente aceptable de la misma y lactosa anhidra; tableta farmaceutica oral; procedimiento de preparacion de dicha tableta, util en el tratamiento de la esquizofren
US8039461B1 (en)	2006-11-10	2011-10-18	Pisgah Laboratories, Inc.	Physical states of a pharmaceutical drug substance
US7718649B1 (en)	2006-11-10	2010-05-18	Pisgah Labs, Inc.	Physical states of a pharmaceutical drug substance
PL381564A1 (pl)	2007-01-22	2008-08-04	Koźluk Tomasz Nobilus Ent	Sposób wytwarzania zasadniczo czystej odmiany polimorficznej I olanzapiny
CA2591644A1 (en) *	2007-06-14	2008-12-14	Apotex Pharmachem Inc.	Novel processes to form-i of olanzapine
US9056488B2 (en)	2007-07-12	2015-06-16	Ncr Corporation	Two-side thermal printer
US8883863B1 (en)	2008-04-03	2014-11-11	Pisgah Laboratories, Inc.	Safety of psuedoephedrine drug products
CN101735239B (zh) *	2008-11-06	2011-08-31	齐鲁制药有限公司	一种无水奥氮平晶型ii的制备方法
EP2292624A1 (de)	2009-07-20	2011-03-09	LEK Pharmaceuticals d.d.	Olanzapinreinigungsverfahren
DK3446565T3 (da)	2010-08-23	2024-01-22	Alkermes Pharma Ireland Ltd	Fremgangsmåder til behandling af antipsykotika-induceret vægtøgning
CN102093386B (zh) *	2011-01-05	2016-06-01	浙江华海药业股份有限公司	一种制备奥兰扎平晶型ⅱ的方法
WO2012153347A2 (en)	2011-05-04	2012-11-15	Zentiva K.S.	Oral pharmaceutical composition of olanzapine form 1
AU2013305901B2 (en)	2012-08-21	2017-10-26	Saladax Biomedical Inc.	Antibodies to olanzapine and use thereof
JP6389177B2 (ja) *	2012-08-21	2018-09-12	ヤンセンファーマシューティカエヌ．ベー．	オランザピンハプテンに対する抗体及びその使用
US9751953B2 (en)	2012-08-21	2017-09-05	Janssen Pharmaceutica Nv	Antibodies to risperidone haptens and use thereof
JP6440625B2 (ja)	2012-11-14	2018-12-19	ザ・ジョンズ・ホプキンス・ユニバーシティー	精神分裂病を処置するための方法および組成物
CN103848847B (zh) *	2012-12-04	2018-02-06	广东东阳光药业有限公司	一种改进制备奥氮平及其晶型ii的方法
JP6008734B2 (ja) *	2012-12-20	2016-10-19	株式会社トクヤマ	オランザピンｉｉ型結晶の製造方法
CN103145731B (zh) *	2013-02-26	2014-02-19	江苏豪森药业股份有限公司	奥氮平晶型及其制备方法和用途
IL314293A (en)	2022-01-20	2024-09-01	Teva Pharmaceuticals Int Gmbh	Olanzapine, its compounds and methods of using it
WO2024149778A1 (en)	2023-01-10	2024-07-18	Medincell Sa	Olanzapine compositions and methods of use

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4115568A (en) *	1974-11-26	1978-09-19	Lilly Industries Limited	Thieno[3,2-b]-[1,5]benzodiazepines
GB1548022A (en)	1976-10-06	1979-07-04	Wyeth John & Brother Ltd	Pharmaceutial dosage forms
CA1097233A (en)	1977-07-20	1981-03-10	George K. E. Gregory	Packages
US4237279A (en) *	1979-07-27	1980-12-02	Eli Lilly And Company	Crystalline 3-hydroxycephalosporin solvates
IE53696B1 (en)	1981-12-02	1989-01-18	Wyeth John & Brother Ltd	Solid shaped articles
US5079018A (en)	1989-08-14	1992-01-07	Neophore Technologies, Inc.	Freeze dry composition and method for oral administration of drugs, biologicals, nutrients and foodstuffs
US5039540A (en)	1989-08-14	1991-08-13	Neophore Technologies, Inc.	Freeze dry composition and method for oral administration of drugs, biologicals, nutrients and foodstuffs
GB9009229D0 (en) *	1990-04-25	1990-06-20	Lilly Industries Ltd	Pharmaceutical compounds
US5229382A (en) *	1990-04-25	1993-07-20	Lilly Industries Limited	2-methyl-thieno-benzodiazepine
EP0582368B1 (de) *	1992-05-29	2001-01-24	Eli Lilly And Company Limited	Thienobenzodiazepinderivate zur Behandlung von Störungen des Zentralnervensystems
US5439888A (en) *	1994-03-04	1995-08-08	Eli Lilly And Company	Antithrombotic agents
US5457101A (en) *	1994-06-03	1995-10-10	Eli Lilly And Company	Thieno[1,5]benzoidiazepine use
EG23659A (en) *	1995-03-24	2007-03-26	Lilly Co Eli	Process and crystal forms of methyl-thieno-benzodiazepine

1996
- 1996-03-21 EG EG19960250A patent/EG23659A/xx active
- 1996-03-22 PT PT00203573T patent/PT1095941E/pt unknown
- 1996-03-22 DK DK96302000T patent/DK0733635T3/da active
- 1996-03-22 DE DE69636313T patent/DE69636313T2/de not_active Expired - Lifetime
- 1996-03-22 CA CA002214005A patent/CA2214005C/en not_active Expired - Fee Related
- 1996-03-22 EA EA199700262A patent/EA000149B1/ru not_active IP Right Cessation
- 1996-03-22 HU HU9802824A patent/HU224989B1/hu not_active IP Right Cessation
- 1996-03-22 AP APAP/P/1997/001065A patent/AP828A/en active
- 1996-03-22 YU YU17796A patent/YU49478B/sh unknown
- 1996-03-22 DE DE69630324T patent/DE69630324T2/de not_active Expired - Lifetime
- 1996-03-22 PL PL96322501A patent/PL183723B1/pl not_active IP Right Cessation
- 1996-03-22 ZA ZA9602344A patent/ZA962344B/xx unknown
- 1996-03-22 MY MYPI96001085A patent/MY114701A/en unknown
- 1996-03-22 UA UA97094737A patent/UA44765C2/uk unknown
- 1996-03-22 RO RO97-01761A patent/RO118872B1/ro unknown
- 1996-03-22 CN CN96192775A patent/CN1065536C/zh not_active Expired - Lifetime
- 1996-03-22 LU LU90096A patent/LU90096B1/fr active
- 1996-03-22 TW TW085103500A patent/TW442488B/zh not_active IP Right Cessation
- 1996-03-22 EP EP00203573A patent/EP1095941B1/de not_active Expired - Lifetime
- 1996-03-22 JP JP8529532A patent/JPH11502535A/ja not_active Ceased
- 1996-03-22 ES ES96302000T patent/ES2159346T3/es not_active Expired - Lifetime
- 1996-03-22 AT AT96302000T patent/ATE204280T1/de active
- 1996-03-22 AT AT0902196A patent/AT406771B/de not_active IP Right Cessation
- 1996-03-22 CZ CZ19973000A patent/CZ292688B6/cs not_active IP Right Cessation
- 1996-03-22 AU AU54279/96A patent/AU706471B2/en not_active Ceased
- 1996-03-22 EP EP96302000A patent/EP0733635B1/de not_active Expired - Lifetime
- 1996-03-22 DE DE69614426T patent/DE69614426T2/de not_active Expired - Lifetime
- 1996-03-22 AR ARP960101875A patent/AR010448A1/es unknown
- 1996-03-22 NZ NZ306110A patent/NZ306110A/en not_active IP Right Cessation
- 1996-03-22 TW TW085103499A patent/TW513432B/zh not_active IP Right Cessation
- 1996-03-22 IL IL11761096A patent/IL117610A/xx not_active IP Right Cessation
- 1996-03-22 SI SI9630345T patent/SI0733635T1/xx unknown
- 1996-03-22 ES ES03077455T patent/ES2266719T3/es not_active Expired - Lifetime
- 1996-03-22 WO PCT/US1996/003917 patent/WO1996030375A1/en active IP Right Grant
- 1996-03-22 ZA ZA9602342A patent/ZA962342B/xx unknown
- 1996-03-22 CO CO96014567A patent/CO4650278A1/es unknown
- 1996-03-22 DK DK00203573T patent/DK1095941T3/da active
- 1996-03-22 TR TR97/01017T patent/TR199701017T1/xx unknown
- 1996-03-22 DE DE19681286T patent/DE19681286T1/de not_active Withdrawn
- 1996-03-22 ES ES00203573T patent/ES2208220T3/es not_active Expired - Lifetime
- 1996-03-22 PE PE1996000203A patent/PE44897A1/es not_active IP Right Cessation
- 1996-03-22 SK SK1218-97A patent/SK284143B6/sk not_active IP Right Cessation
- 1996-03-22 AT AT00203573T patent/ATE251627T1/de active
- 1996-03-22 AR ARP960101876A patent/AR002719A1/es unknown
- 1996-03-22 GB GB9719819A patent/GB2313835B/en not_active Expired - Fee Related
- 1996-03-22 CH CH02245/97A patent/CH690579A5/de not_active IP Right Cessation
- 1996-03-22 DK DK03077455T patent/DK1445259T3/da active
- 1996-03-22 SI SI9630636T patent/SI1095941T1/xx unknown
- 1996-03-22 BR BR9607790A patent/BR9607790A/pt not_active IP Right Cessation
- 1996-03-22 PT PT03077455T patent/PT1445259E/pt unknown
- 1996-03-22 EE EE9700232A patent/EE03489B1/xx not_active IP Right Cessation
- 1996-03-22 EP EP03077455A patent/EP1445259B1/de not_active Expired - Lifetime
- 1996-03-22 SI SI9620040A patent/SI9620040B/sl not_active IP Right Cessation
- 1996-03-22 PT PT96302000T patent/PT733635E/pt unknown
- 1996-03-22 SI SI9630743T patent/SI1445259T1/sl unknown
- 1996-03-22 KR KR1019970706591A patent/KR100399688B1/ko not_active IP Right Cessation
- 1996-03-22 AT AT03077455T patent/ATE331719T1/de active
- 1996-05-09 SV SV1996000031A patent/SV1996000031A/es not_active Application Discontinuation
- 1996-07-25 US US08/686,989 patent/US5736541A/en not_active Expired - Lifetime
- 1996-10-18 PA PA19968353701A patent/PA8353701A1/es unknown
1997
- 1997-09-05 SE SE9703205A patent/SE9703205D0/xx not_active Application Discontinuation
- 1997-09-08 LV LVP-97-163A patent/LV12018B/en unknown
- 1997-09-16 LT LT97-148A patent/LT4349B/lt not_active IP Right Cessation
- 1997-09-22 BG BG101900A patent/BG62619B1/bg unknown
- 1997-09-22 FI FI973750A patent/FI973750L/fi unknown
- 1997-09-22 IS IS4564A patent/IS1896B/is unknown
- 1997-09-22 NO NO19974365A patent/NO314663B1/no not_active IP Right Cessation
- 1997-09-23 DK DK108997A patent/DK108997A/da not_active Application Discontinuation
- 1997-09-24 OA OA70082A patent/OA10510A/en unknown
1998
- 1998-12-23 HK HK98115175A patent/HK1013988A1/xx not_active IP Right Cessation

Also Published As

Publication number	Publication date
AT406771B (de)	2000-08-25
MX9707183A (es)	1997-11-29
DE69636313T2 (de)	2007-05-31
PL183723B1 (pl)	2002-07-31
SK284143B6 (sk)	2004-10-05
AR002719A1 (es)	1998-04-29
GB2313835A (en)	1997-12-10
PL322501A1 (en)	1998-02-02
IL117610A (en)	2001-08-26
EP0733635B1 (de)	2001-08-16
BG101900A (en)	1999-03-31
NO314663B1 (no)	2003-04-28
TW513432B (en)	2002-12-11
EP1095941A1 (de)	2001-05-02
SI1445259T1 (sl)	2006-10-31
YU17796A (sh)	1999-03-04
EP1095941B1 (de)	2003-10-08
US5736541A (en)	1998-04-07
CA2214005C (en)	2001-07-03
GB9719819D0 (en)	1997-11-19
SE9703205L (sv)	1997-09-05
DE69630324D1 (de)	2003-11-13
CO4650278A1 (es)	1998-09-03
LT97148A (en)	1998-01-26
CZ292688B6 (cs)	2003-11-12
EE03489B1 (et)	2001-08-15
BG62619B1 (bg)	2000-03-31
ES2266719T3 (es)	2007-03-01
AP828A (en)	2000-04-28
NO974365D0 (no)	1997-09-22
CH690579A5 (de)	2000-10-31
DE69614426T2 (de)	2002-05-23
CA2214005A1 (en)	1996-10-03
PA8353701A1 (es)	1998-09-18
PT1445259E (pt)	2006-10-31
DK1095941T3 (da)	2004-02-16
HU224989B1 (en)	2006-05-29
LU90096B1 (fr)	1997-07-22
SI0733635T1 (en)	2002-06-30
SE9703205D0 (sv)	1997-09-05
HUP9802824A3 (en)	2000-01-28
PE44897A1 (es)	1997-10-22
OA10510A (en)	2002-04-24
ZA962342B (en)	1997-09-22
SI9620040B (sl)	2002-02-28
NO974365L (no)	1997-09-22
SI9620040A (sl)	1998-06-30
HK1013988A1 (en)	1999-09-17
UA44765C2 (uk)	2002-03-15
JPH11502535A (ja)	1999-03-02
GB2313835B (en)	1998-09-16
LV12018A (lv)	1998-04-20
ZA962344B (en)	1997-09-22
DK1445259T3 (da)	2006-10-16
LT4349B (lt)	1998-05-25
AU706471B2 (en)	1999-06-17
ATE251627T1 (de)	2003-10-15
SK121897A3 (en)	1998-03-04
NZ306110A (en)	1998-09-24
AP9701065A0 (en)	1997-10-31
AR010448A1 (es)	2000-06-28
EE9700232A (et)	1998-04-15
SI1095941T1 (en)	2003-12-31
MY114701A (en)	2002-12-31
ES2208220T3 (es)	2004-06-16
FI973750A0 (fi)	1997-09-22
CZ300097A3 (en)	1997-12-17
AU5427996A (en)	1996-10-16
EP1445259A1 (de)	2004-08-11
ES2159346T3 (es)	2001-10-01
EP1445259B1 (de)	2006-06-28
HUP9802824A2 (hu)	1999-06-28
DE69630324T2 (de)	2004-07-29
PT1095941E (pt)	2004-02-27
DK108997A (da)	1997-11-12
CN1065536C (zh)	2001-05-09
CN1179160A (zh)	1998-04-15
IL117610A0 (en)	1996-07-23
KR19980703188A (ko)	1998-10-15
PT733635E (pt)	2001-12-28
EG23659A (en)	2007-03-26
EA000149B1 (ru)	1998-10-29
LV12018B (en)	1998-09-20
IS4564A (is)	1997-09-22
KR100399688B1 (ko)	2004-02-18
ATE204280T1 (de)	2001-09-15
ATE331719T1 (de)	2006-07-15
DE19681286T1 (de)	1998-04-02
TW442488B (en)	2001-06-23
SV1996000031A (es)	1998-03-27
RO118872B1 (ro)	2003-12-30
DK0733635T3 (da)	2001-10-08
DE69614426D1 (de)	2001-09-20
IS1896B (is)	2003-10-20
EP0733635A1 (de)	1996-09-25
ATA902196A (de)	2000-01-15
TR199701017T1 (xx)	1998-01-21
FI973750L (fi)	1997-09-22
YU49478B (sh)	2006-05-25
WO1996030375A1 (en)	1996-10-03
BR9607790A (pt)	1998-07-07
EA199700262A1 (ru)	1998-02-26

Publication	Publication Date	Title
ATE331719T1 (de)	2006-07-15	Verwendung von kristallformen von 2- methylthienobenzodiazepinen
DE69634998D1 (de)	2005-09-01	Kontrolle von Kanten
DE69631647D1 (de)	2004-04-01	Erfassung von möglichem betrügerischen gebrauch von kommunikation
DE69431880D1 (de)	2003-01-23	Verwendung von (2-imidazolin-2-yl-amino) quinoxalinderivaten
DE69636449D1 (de)	2006-09-28	Armbanduhr-funktelefon
DE69626729D1 (de)	2003-04-24	Kombination von Datenwerten
DE69533361D1 (de)	2004-09-16	Umsetzung von kohlenwasserstoffen
DE69628195D1 (de)	2003-06-18	Verwendung von xyloglucanendotransglycosylase
NL300284I2 (nl)	2007-11-01	Kristalmodificatie van
ATE172762T1 (de)	1998-11-15	Verwendung von ethylenaminen bei der lignin- entfernung
DE69531048D1 (de)	2003-07-17	Verwendung von steroidsulphatase-hemmern
DE69827393D1 (de)	2004-12-09	Kosmetische verwendung von bis-resorcinol-triazinderivaten
DE59610014D1 (de)	2003-02-06	Schwingquarzsensor
DE69612725D1 (de)	2001-06-13	Kristallhaltevorrichtung
DE59401861D1 (de)	1997-04-03	Verwendung von ferrocen
DE69605708D1 (de)	2000-01-27	Reinigung von Pentafluorethan
DE69606449D1 (de)	2000-03-09	Züchtung von Silizium-Einkristall
DE19681567T1 (de)	1998-10-15	Flüssigkristallzusammensetzung
DE59607408D1 (de)	2001-09-06	Mischungen von Monoazopyridonfarbstoffen
DE69515021D1 (de)	2000-03-16	Ausrichtung von Interferometern
DE69508469D1 (de)	1999-04-29	Oxyde-Granat-Einkristall
DE59308823D1 (de)	1998-09-03	Verwendung von Thioalkandionen als Aromastoffe
ATE210605T1 (de)	2001-12-15	Verwendung von sulfonamiden zur kontrolle von biobewuchs
DE69623886D1 (de)	2002-10-31	Entfernung von Spleissbändern
DE59501871D1 (de)	1998-05-20	Monocarbonsäureamide von Polyaminen

Legal Events

Date	Code	Title	Description
2007-07-19	8364	No opposition during term of opposition
2010-05-20	8328	Change in the person/name/address of the agent	Representative=s name: KROHER, STROBEL RECHTS- UND PATENTANWAELTE, 80336
2011-06-16	8328	Change in the person/name/address of the agent	Representative=s name: DR. SCHOEN & PARTNER, 80336 MUENCHEN